LivaNova (NASDAQ:LIVN) Issues FY 2025 Earnings Guidance

LivaNova (NASDAQ:LIVN) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 3.650-3.750 for the period, compared to the consensus EPS estimate of 3.630. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion. LivaNova also updated its FY25 guidance to $3.65-3.75 EPS.

LivaNova Trading Down 1.4 %

LIVN stock traded down $0.56 during trading on Thursday, reaching $40.89. 239,774 shares of the stock were exchanged, compared to its average volume of 560,286. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of 97.35 and a beta of 1.00. The business has a 50 day moving average price of $47.65 and a 200-day moving average price of $49.56. LivaNova has a 1 year low of $40.37 and a 1 year high of $64.47.

Analysts Set New Price Targets

A number of research firms recently commented on LIVN. Stifel Nicolaus decreased their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday. StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Needham & Company LLC cut their target price on LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday. Robert W. Baird boosted their target price on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, Mizuho cut their target price on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $64.20.

Insider Transactions at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares in the company, valued at $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.27% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.